Drugs /

elacestrant

Back to Drugs List

Overview

NCI Definition [1]:
An orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and estrogen-like activities. Upon oral administration of higher doses of elacestrant, this agent acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells. At lower doses of this agent, RAD1901 acts as a SERM and has estrogen-like effects in certain tissues, which can both reduce hot flashes and protect against bone loss. In addition, elacestrant is able to cross the blood-brain barrier (BBB).

Clinical Trials

View Clinical Trials for elacestrant

Elacestrant has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating elacestrant, 1 is phase 1 (0 open) and 1 is phase 3 (1 open).

ER Positive, HER2 Deficient Expression, and HER2 Negative are the most frequent biomarker inclusion criteria for elacestrant clinical trials.

Breast adenocarcinoma and breast carcinoma are the most common diseases being investigated in elacestrant clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Elacestrant
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Elacestrant
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating elacestrant and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
er-306323, (6r)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol, rad1901, serd/serm rad1901
NCIT ID [1]:
C120211

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.